PA · State regulatory reference
Pennsylvania.
Moderate
No dedicated telemedicine practice statute — the State Board of Medicine applies the general 'acceptable and prevailing standard of care,' and for non-controlled drugs there is no explicit in-person-exam requirement. Compounding runs under 49 Pa. Code §§ 27.601-27.606 (effective 2019), which incorporates FDCA § 503A and the current USP chapters by reference. The distinctive signal is one flagship enforcement action: in October 2025 the State Board of Pharmacy imposed a $1 million penalty on Boothwyn Pharmacy for compounding roughly 30,000 doses of GLP-1 weight-loss drugs in unlicensed, uninspected facilities — an egregious-actor case, not evidence of broad strictness.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
Standard-of-care framework with no statutory new-patient in-person requirement for non-controlled drugs; audio-only is permitted. Controlled substances separately require an initial history and physical under 49 Pa. Code § 16.92.
Compounding
49 Pa. Code §§ 27.601-27.606 require sterile and nonsterile compounding to meet FDCA § 503A and current USP chapters (795/797, and 800 for hazardous drugs); the state adds no major idiosyncratic requirements.
Sources
- 01 PA Dept. of State — Telemedicine FAQs (Board of Medicine standard-of-care posture) ↗
- 02 PA Dept. of State — $1M penalty against Boothwyn Pharmacy for unlawful GLP-1 compounding (Oct. 21, 2025) ↗
- 03 Pennsylvania Bulletin — Board of Pharmacy compounding regs, 49 Pa. Code §§ 27.601-27.606 (eff. June 22, 2019) ↗